Ligand Pharmaceuticals (LGND) Intangibles (2010 - 2026)

Ligand Pharmaceuticals has disclosed Intangibles across 17 years of filings, most recently posting $217.3 million for Q1 2026.

• Intangibles for Q1 2026 came in at $217.3 million, down 15.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $217.3 million (down 15.89% YoY), and the FY2025 annual result was $225.4 million, down 15.45% from the prior year.
• Intangibles came in at $217.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $225.4 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $539.7 million in Q1 2022 to a low of $217.3 million in Q1 2026.
• The 5-year median for Intangibles is $291.4 million (2024), against an average of $323.7 million.
• Across the five-year window, Intangibles declined 7.55% in 2022 and plunged 39.1% in 2023, its largest moves.
• Ligand Pharmaceuticals' Intangibles stood at $342.5 million in 2022, then declined by 12.51% to $299.6 million in 2023, then decreased by 11.0% to $266.6 million in 2024, then fell by 15.45% to $225.4 million in 2025, then retreated by 3.59% to $217.3 million in 2026.
• The last three Intangibles figures came in at $217.3 million (Q1 2026), $225.4 million (Q4 2025), and $233.5 million (Q3 2025), per Business Quant data.